Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFOX6 or CapeOx (Roche)
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
mFOLFOX6 and CapeOx are standard-of-care adjuvant chemotherapy regimens for colorectal cancer. mFOLFOX6 consists of oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil (5-FU), typically administered via intravenous infusion. CapeOx (also known as XELOX) consists of oral capecitabine and intravenous oxaliplatin. Both regimens aim to eliminate residual cancer cells post-surgery by inhibiting DNA synthesis and repair. Oxaliplatin acts as a platinum-based DNA cross-linking agent, while 5-FU and its prodrug capecitabine inhibit thymidylate synthase. Leucovorin is used in mFOLFOX6 to enhance the binding of 5-FU to its target. In the context of the provided trial, these regimens serve as the control arm for comparison against the more intensive mFOLFOXIRI regimen in patients with stage IIIB or IIIC colorectal cancer.
- Other names
- mFOLFOX6mFOLFOX-6mFOLFOX 6CapeOxXELOXmodified FOLFOX6Capecitabine plus OxaliplatinmFOLFOX6/CapeOx
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on mFOLFOX6 or CapeOx (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFOX6 or CapeOx (Roche).